The Psychiatric Disease Pipeline: A Strategic Review

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• The Psychiatric Disease Pipeline by the Numbers
• Companies Developing Psychiatric Disease Agents
  • GlaxoSmithKline
  • AstraZeneca
• Opportunities and Challenges in the Psychiatric Disease Market
  • Important Market Opportunities for Psychiatric Diseases
    • High Unmet Need for Treatment-Resistant and Bipolar Depression
    • Cognitive Impairment Associated with Schizophrenia
  • Challenges Facing Companies with Emerging Psychiatric Agents
    • Increased Treatment by PCPs Challenges Emerging Therapy Uptake
    • Reimbursement Issues Loom Large for Existing and New Agents Alike
• Outlook: Strategies for Developers in a Challenging Sector
  • Current Market Statistics
  • Strategies for Emerging Agents

Tables

• 1. Psychiatric Disease Descriptions
• 2. Drug Classes Commonly Prescribed to Treat Psychiatric Disease
• 3. Unmet Needs in Psychiatric Disease
• 4. GlaxoSmithKline' s Psychiatric Pipeline
• 5. AstraZeneca' s Psychiatric Pipeline
• 6. Agents in Development for the Treatment of Cognitive Impairment Associated with Schizophrenia
• 7. Top-Selling Psychiatric Drugs, 2008

Figures

• 1. The Psychiatric Pipeline, NMEs vs. Reformulations
• 2. The Psychiatric Pipeline, by Target
• 3. The Psychiatric Pipeline, by Disease
• 4. The Psychiatric Pipeline, by Phase of Development
• 5. Leading Psychiatric Pipelines, by Company
• 6. Psychiatric Pipeline Development Activity, by Company Size
• 7. GlaxoSmithKline' s Psychiatric Drug Sales, 2003-2008
• 8; Market Share of Psychiatric Drug Classes, 2008
• 9. Psychiatric Market Growth, 2003-2008